Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
GeneDx Holdings Corp. (WGSWW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/15/2025: WGSWW (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -61.11% | Avg. Invested days 27 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/15/2025 |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta 2.01 | 52 Weeks Range 0.02 - 0.34 | Updated Date 05/17/2025 |
52 Weeks Range 0.02 - 0.34 | Updated Date 05/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -11.69% | Operating Margin (TTM) -5.22% |
Management Effectiveness
Return on Assets (TTM) -1.84% | Return on Equity (TTM) -16.61% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating 19433395 |
Shares Outstanding - | Shares Floating 19433395 | ||
Percent Insiders - | Percent Institutions - |
Upturn AI SWOT
GeneDx Holdings Corp.
Company Overview
History and Background
GeneDx Holdings Corp. (formerly Sema4) was founded in 2000 as GeneDx, a division of BioReference Laboratories, and later spun out as an independent entity before merging with CM Life Sciences II and rebranding as GeneDx Holdings Corp. It has grown to become a leader in genomic testing for rare disorders.
Core Business Areas
- Rare Disease Testing: Offers comprehensive genomic testing for individuals and families affected by rare genetic disorders, including whole exome sequencing (WES), whole genome sequencing (WGS), and targeted gene panels.
- Reproductive Health Testing: Provides genetic screening and testing services for couples planning a family, including carrier screening and preimplantation genetic testing (PGT).
Leadership and Structure
GeneDx Holdings Corp. is led by a management team with expertise in genomics, diagnostics, and healthcare. The organizational structure is hierarchical, with functional departments such as research and development, sales and marketing, and operations.
Top Products and Market Share
Key Offerings
- Whole Exome Sequencing (WES): A comprehensive test that sequences all protein-coding genes in the genome. Market share is difficult to ascertain precisely but considered significant within the rare disease diagnostics segment, which is growing rapidly. Competitors include Invitae, PerkinElmer, and Quest Diagnostics.
- Whole Genome Sequencing (WGS): Sequences the entire genome, including non-coding regions. Market share is smaller than WES but growing due to increased diagnostic yield. Competitors include Illumina, PacBio, and other specialized genomics labs.
- Rapid Whole Genome Sequencing (rWGS): Sequencing the entire genome with rapid turnaround time for urgent clinical situations. The rapid and thorough nature of the test can enable improved clinical care, and inform clinical management for critically ill neonates and children. Competitors include Rady Children's Institute for Genomic Medicine, Illumina
Market Dynamics
Industry Overview
The genetic testing market is experiencing rapid growth, driven by technological advancements, decreasing sequencing costs, and increasing awareness of the role of genetics in health and disease.
Positioning
GeneDx Holdings Corp. is positioned as a leader in rare disease diagnostics, with a strong focus on providing comprehensive genomic testing services and expert interpretation. It holds a strong reputation among clinicians specializing in rare diseases.
Total Addressable Market (TAM)
The total addressable market for genetic testing is estimated to be billions of dollars and is expected to continue to grow. GeneDx Holdings Corp. is positioned to capture a significant share of this market through its comprehensive testing offerings and focus on rare diseases.
Upturn SWOT Analysis
Strengths
- Strong expertise in rare disease diagnostics
- Comprehensive genomic testing portfolio
- Established relationships with clinicians and researchers
- High-quality data and interpretation
Weaknesses
- Financial losses
- High operating expenses
- Dependence on reimbursement from payers
- Relatively small market capitalization
Opportunities
- Expanding genomic testing services to new markets
- Developing new diagnostic tests and technologies
- Partnering with pharmaceutical companies to develop targeted therapies
- Increasing awareness of the benefits of genomic testing
Threats
- Competition from other genetic testing companies
- Changes in reimbursement policies
- Data privacy and security concerns
- Regulatory changes
Competitors and Market Share
Key Competitors
- ILMN
- NVTA
- DGX
- LH
Competitive Landscape
GeneDx Holdings Corp. faces competition from larger, more established genetic testing companies and specialized genomics laboratories. Its competitive advantages include its expertise in rare disease diagnostics and its comprehensive genomic testing portfolio. However, its financial losses are a significant disadvantage.
Growth Trajectory and Initiatives
Historical Growth: GeneDx Holdings Corp. has experienced rapid revenue growth in recent years, driven by increased demand for genomic testing services.
Future Projections: Future growth is expected to be driven by expanding genomic testing services to new markets, developing new diagnostic tests and technologies, and increasing awareness of the benefits of genomic testing. Analyst estimates vary based on the company's ability to achieve profitability.
Recent Initiatives: Recent initiatives include expanding partnerships with pharmaceutical companies and healthcare providers, launching new genomic testing services, and investing in research and development.
Summary
GeneDx Holdings Corp. is a leader in rare disease genomic testing with a comprehensive portfolio, but faces significant challenges with financial losses and strong competition. While expertise and comprehensive testing are strengths, achieving profitability and navigating reimbursement policies are crucial for long-term success. It needs to carefully monitor its financials and competition to capitalize on growth opportunities in the expanding genetic testing market.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings
- Analyst reports
- Industry publications
Disclaimers:
The information provided is for informational purposes only and should not be construed as investment advice. Market share estimates are approximate and may vary depending on the source.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About GeneDx Holdings Corp.
Exchange NASDAQ | Headquaters Stamford, CT, United States | ||
IPO Launch date 2020-10-29 | President, CEO & Director Ms. Katherine A. Stueland | ||
Sector Healthcare | Industry Diagnostics & Research | Full time employees 1000 | Website https://www.genedx.com |
Full time employees 1000 | Website https://www.genedx.com | ||
GeneDx Holdings Corp., a genomics company, provides genetic testing services. It primarily offers pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing, as well as data and information services. The company also develops an AI-based platform for NGS analysis, interpretation, and clinical reporting for rare disease, hereditary risk, and cancer testing. The company is headquartered in Stamford, Connecticut.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.